Central Nervous System Involvement in Burkitt's Lymphoma

Thirty-five of 77 patients (46%) with Burkitt's lymphoma presented or developed evidence of central nervous system involvement by tumor. Neurologic abnormalities included paraplegia, cranial neuropathy, altered levels of consciousness and malignant pleocytosis. An analysis of this series disclo...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1970-12, Vol.36 (6), p.718-728
Main Authors: ZIEGLER, JOHN L., BLUMING, AVRUM Z., MORROW, RICHARD H., FASS, LEROY, CARBONE, PAUL P.
Format: Article
Language:English
Subjects:
Brain Neoplasms
Burkitt Lymphoma - complications
Burkitt Lymphoma - drug therapy
Central Nervous System Diseases - drug therapy
Central Nervous System Diseases - etiology
Cerebrospinal Fluid - cytology
Cognition Disorders - etiology
Cyclophosphamide - therapeutic use
Cytarabine - therapeutic use
Folic Acid - therapeutic use
Humans
Injections, Spinal
Lymphocytosis - etiology
Methotrexate - administration & dosage
Neoplasm Metastasis
Paraplegia - etiology
Vincristine - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thirty-five of 77 patients (46%) with Burkitt's lymphoma presented or developed evidence of central nervous system involvement by tumor. Neurologic abnormalities included paraplegia, cranial neuropathy, altered levels of consciousness and malignant pleocytosis. An analysis of this series disclosed the following: Paraplegia is a common presenting feature of Burkitt's lymphoma and is responsive to systemic chemotherapy. The association of cranial neuropathy and malignant pleocytosis with facial tumors points to direct tumor extension to intracranial structures (duraarachnoid) as the pathogenesis of these lesions. Intrathecal chemotherapy temporarily reverses malignant pleocytosis but systemic chemotherapy is required to treat cranial neuropathy. A poor prognosis follows presentation or development of malignant pleocytosis. The limitations of the current forms of therapy for CNS involvement are discussed.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V36.6.718.718